Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease

Noble George, Emily Gean, Ayon Nandi, James R Brasic, Dean Foster Wong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Alzheimer's disease (AD) being the most common form of dementia in individuals over the age of 65 years and with an ever-aging global population, the prevalence of the disease is expected to double in the next 10 years. With the associated high cost, and burden on caregivers, it is imperative that we develop sensitive biomarkers to aid in the diagnosis and treatment for the monitoring of these patients. In recent years, there has been a significant improvement in positron emission tomography (PET) scanner technology and development of new radiotracers that are more target specific.PET imaging of the brain has proven to be the most accurate noninvasive method of not only diagnosing and differentiating the different types of dementia but also predicting the likelihood of developing the disease. Brain PET imaging in combination with pathology may also aid in evaluating the various hypotheses of AD pathogenesis.Although no curative treatment currently exists, the development of novel medications is very much active in many clinical trials. PET imaging will continue to play a significant role in these developments. In this chapter, we will review the various amyloid imaging radiotracers, novel as well as existing, and expand upon their potentials, pitfalls, and relative comparison.

Original languageEnglish (US)
Title of host publicationImaging of the Human Brain in Health and Disease
PublisherElsevier Inc.
Pages407-416
Number of pages10
ISBN (Print)9780124186774
DOIs
StatePublished - 2013

Fingerprint

Positron-Emission Tomography
Alzheimer Disease
Brain
Dementia
Physiologic Monitoring
Amyloid
Neuroimaging
Caregivers
Biomarkers
Clinical Trials
Pathology
Technology
Costs and Cost Analysis
Therapeutics
Population

Keywords

  • Alzheimer's disease
  • AV-45
  • FDDNP
  • FDG
  • Florbetaben
  • Flutemetamol
  • MK-3328
  • PIB
  • Positron emission tomography
  • Radiotracers
  • THK523

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

George, N., Gean, E., Nandi, A., Brasic, J. R., & Wong, D. F. (2013). Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. In Imaging of the Human Brain in Health and Disease (pp. 407-416). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-418677-4.00016-6

Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. / George, Noble; Gean, Emily; Nandi, Ayon; Brasic, James R; Wong, Dean Foster.

Imaging of the Human Brain in Health and Disease. Elsevier Inc., 2013. p. 407-416.

Research output: Chapter in Book/Report/Conference proceedingChapter

George, N, Gean, E, Nandi, A, Brasic, JR & Wong, DF 2013, Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. in Imaging of the Human Brain in Health and Disease. Elsevier Inc., pp. 407-416. https://doi.org/10.1016/B978-0-12-418677-4.00016-6
George N, Gean E, Nandi A, Brasic JR, Wong DF. Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. In Imaging of the Human Brain in Health and Disease. Elsevier Inc. 2013. p. 407-416 https://doi.org/10.1016/B978-0-12-418677-4.00016-6
George, Noble ; Gean, Emily ; Nandi, Ayon ; Brasic, James R ; Wong, Dean Foster. / Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. Imaging of the Human Brain in Health and Disease. Elsevier Inc., 2013. pp. 407-416
@inbook{75eee66cf7214efb951404ba2b6e49ad,
title = "Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease",
abstract = "Alzheimer's disease (AD) being the most common form of dementia in individuals over the age of 65 years and with an ever-aging global population, the prevalence of the disease is expected to double in the next 10 years. With the associated high cost, and burden on caregivers, it is imperative that we develop sensitive biomarkers to aid in the diagnosis and treatment for the monitoring of these patients. In recent years, there has been a significant improvement in positron emission tomography (PET) scanner technology and development of new radiotracers that are more target specific.PET imaging of the brain has proven to be the most accurate noninvasive method of not only diagnosing and differentiating the different types of dementia but also predicting the likelihood of developing the disease. Brain PET imaging in combination with pathology may also aid in evaluating the various hypotheses of AD pathogenesis.Although no curative treatment currently exists, the development of novel medications is very much active in many clinical trials. PET imaging will continue to play a significant role in these developments. In this chapter, we will review the various amyloid imaging radiotracers, novel as well as existing, and expand upon their potentials, pitfalls, and relative comparison.",
keywords = "Alzheimer's disease, AV-45, FDDNP, FDG, Florbetaben, Flutemetamol, MK-3328, PIB, Positron emission tomography, Radiotracers, THK523",
author = "Noble George and Emily Gean and Ayon Nandi and Brasic, {James R} and Wong, {Dean Foster}",
year = "2013",
doi = "10.1016/B978-0-12-418677-4.00016-6",
language = "English (US)",
isbn = "9780124186774",
pages = "407--416",
booktitle = "Imaging of the Human Brain in Health and Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease

AU - George, Noble

AU - Gean, Emily

AU - Nandi, Ayon

AU - Brasic, James R

AU - Wong, Dean Foster

PY - 2013

Y1 - 2013

N2 - Alzheimer's disease (AD) being the most common form of dementia in individuals over the age of 65 years and with an ever-aging global population, the prevalence of the disease is expected to double in the next 10 years. With the associated high cost, and burden on caregivers, it is imperative that we develop sensitive biomarkers to aid in the diagnosis and treatment for the monitoring of these patients. In recent years, there has been a significant improvement in positron emission tomography (PET) scanner technology and development of new radiotracers that are more target specific.PET imaging of the brain has proven to be the most accurate noninvasive method of not only diagnosing and differentiating the different types of dementia but also predicting the likelihood of developing the disease. Brain PET imaging in combination with pathology may also aid in evaluating the various hypotheses of AD pathogenesis.Although no curative treatment currently exists, the development of novel medications is very much active in many clinical trials. PET imaging will continue to play a significant role in these developments. In this chapter, we will review the various amyloid imaging radiotracers, novel as well as existing, and expand upon their potentials, pitfalls, and relative comparison.

AB - Alzheimer's disease (AD) being the most common form of dementia in individuals over the age of 65 years and with an ever-aging global population, the prevalence of the disease is expected to double in the next 10 years. With the associated high cost, and burden on caregivers, it is imperative that we develop sensitive biomarkers to aid in the diagnosis and treatment for the monitoring of these patients. In recent years, there has been a significant improvement in positron emission tomography (PET) scanner technology and development of new radiotracers that are more target specific.PET imaging of the brain has proven to be the most accurate noninvasive method of not only diagnosing and differentiating the different types of dementia but also predicting the likelihood of developing the disease. Brain PET imaging in combination with pathology may also aid in evaluating the various hypotheses of AD pathogenesis.Although no curative treatment currently exists, the development of novel medications is very much active in many clinical trials. PET imaging will continue to play a significant role in these developments. In this chapter, we will review the various amyloid imaging radiotracers, novel as well as existing, and expand upon their potentials, pitfalls, and relative comparison.

KW - Alzheimer's disease

KW - AV-45

KW - FDDNP

KW - FDG

KW - Florbetaben

KW - Flutemetamol

KW - MK-3328

KW - PIB

KW - Positron emission tomography

KW - Radiotracers

KW - THK523

UR - http://www.scopus.com/inward/record.url?scp=84940223543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940223543&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-418677-4.00016-6

DO - 10.1016/B978-0-12-418677-4.00016-6

M3 - Chapter

AN - SCOPUS:84940223543

SN - 9780124186774

SP - 407

EP - 416

BT - Imaging of the Human Brain in Health and Disease

PB - Elsevier Inc.

ER -